Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02633527
Other study ID # 812P202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 1, 2016
Est. completion date July 25, 2016

Study information

Verified date August 2020
Source Supernus Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.


Description:

This study is a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy, safety, and tolerability of SPN-812 (Viloxazine Extended-release Capsule) as monotherapy in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children (6-12 years of age). Subjects are randomized in a 1:2:2:2:2 ratio to receive placebo or one of four active treatments (100 mg, 200 mg, 300 mg, or 400 mg SPN-812). The primary objective is to assess the efficacy of SPN-812 in reducing ADHD symptoms as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV).


Recruitment information / eligibility

Status Completed
Enrollment 222
Est. completion date July 25, 2016
Est. primary completion date July 25, 2016
Accepts healthy volunteers No
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: 1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM IV), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). 2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26. 3. CGI-S score of at least 4 4. Weight of at least 20 kg. 5. Free of medication for the treatment of ADHD or any psychosis for at least one week prior to enrollment. Exclusion Criteria: 1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified. 2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as primary diagnosis. 3. Significant systemic disease. 4. Evidence of suicidality within the six months before Screening or at Screening. 5. BMI greater than 95th percentile for the appropriate age and gender. 6. Pregnancy or refusal to practice abstinence during the study for female subjects of childbearing potential (FOCP). 7. Substance or alcohol use during the last three months. 8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.

Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Intervention

Drug:
Placebo
Placebo was administered once daily
100mg SPN-812
100mg SPN-812 was administered once daily and compared to placebo
200mg SPN-812
200mg SPN-812 was administered once daily and compared to placebo
300mg SPN-812
300mg SPN-812 was administered once daily and compared to placebo
400mg SPN-812
400mg SPN-812 was administered once daily and compared to placebo

Locations

Country Name City State
United States Florida Clinical Research Center, LLC Maitland Florida

Sponsors (1)

Lead Sponsor Collaborator
Supernus Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) The Primary Endpoint was the change from baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) Total score at Week 8 (End of Study). The ADHD-RS-IV is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. The scale consists of 18 items that directly correspond to the 18 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of ADHD. Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). A Total score is calculated by adding the responses of all 18 items (range: 0-54; the higher the score, the more severe the ADHD symptoms). Lower change from baseline scores (<0) represent a better outcome. Baseline to Week 8 (End of Study)
Secondary Effect of SPN-812 on Clinical Global Impression - Improvement (CGI-I) Scale The first additional secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) Scale score at Week 8 (End of Study). The CGI-I scale is a single item assessment of how much the patient's illness has improved or worsened relative to a baseline state prior to the beginning of treatment. The CGI-I is rated on a 7-point Likert scale from 1 to 7, where 1 = "Very much improved", 2 = "Much improved", 3 = "Minimally improved", 4 = "No change", 5 = "Minimally worse", 6 = "Much worse", and 7 = "Very much worse". Successful therapy is indicated by a lower score (<4) in subsequent testing. Week 8 (End of Study)
Secondary Effect of SPN-812 on the Clinical Global Impression - Severity (CGI-S) Scale The second additional secondary endpoint was the change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale score at Week 8 (End of Study). The CGI-S scale is a single item clinician/investigator rating of the clinician's assessment of the severity of the ADHD symptoms in relation to the clinician's total experience with patients with ADHD. The CGI-S was rated on a 7-point Likert scale, where 1 = Normal, not at all ill, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Extremely Ill. Successful therapy is indicated by a lower CGI-S score in subsequent testing. A lower change from baseline score (<0) represents a better outcome. Baseline to Week 8 (End of Study)
See also
  Status Clinical Trial Phase
Completed NCT02150668 - Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD N/A
Completed NCT00631280 - Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD N/A
Recruiting NCT05809388 - Virtual Reality for Parent Training Intervention N/A
Completed NCT00776009 - Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. Phase 4
Recruiting NCT00252278 - Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Phase 4
Completed NCT04016779 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Phase 3
Completed NCT00307268 - Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD N/A
Completed NCT01107496 - Evaluation of Immediate-Release Viloxazine in Adults With ADHD Phase 1/Phase 2
Completed NCT04786990 - Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD Phase 4
Completed NCT00475735 - A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) Phase 2
Completed NCT00711724 - Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD N/A
Recruiting NCT06215144 - Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD Phase 2/Phase 3
Withdrawn NCT00323700 - A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD) N/A
Not yet recruiting NCT04532190 - Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder N/A
Withdrawn NCT00931398 - Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate Phase 4